Four versus Two Years of Rituximab Maintenance (R-Maintenance) Following Bendamustine Plus Rituximab (B-R): Results of a Prospective, Randomized Multicenter Phase 3 Study in First-Line Follicular Lymphoma (the StiL NHL7-2008 MAINTAIN Study)

被引：3

作者：

Rummel, Mathias ^{[1
]}

Buske, Christian ^{[2
]}

Hertenstein, Bernd ^{[3
]}

Lerchenmueller, Christian ^{[4
]}

Koenigsmann, Michael ^{[5
]}

Lange, Elisabeth ^{[6
]}

Reeb, Manfred ^{[7
]}

Kaiser, Ulrich ^{[8
]}

Balser, Christina

Behringer, Dirk ^{[9
]}

Duerig, Jan ^{[10
]}

Gaska, Tobias ^{[11
]}

Maschmeyer, Georg ^{[12
]}

Schliesser, Georg

Burchardt, Alexander C. ^{[1
]}

Barth, Juergen ^{[1
]}

Kauff, Frank ^{[1
]}

Hinke, Axel ^{[13
]}

Greil, Richard ^{[14
]}

机构：

[1] Univ Hosp Giessen, Med Clin 4, Hematol, Giessen, Germany

[2] Univ Hosp Ulm, Comprehens Canc Ctr Ulm, Inst Expt Canc Res, Ulm, Germany

[3] Klinikum Bremen Mitte, Med Klin 1, Bremen, Germany

[4] Outpatient Clin, Hematol & Oncol, Munster, Germany

[5] Outpatient Oncol Ctr, Hannover, Germany

[6] Evangel Krankenhaus Hamm, Hamm, Germany

[7] IDGGQ GbR, Kaiserslautern, Germany

[8] St Bernward Hosp, Hildesheim, Germany

[9] Augusta Kranken Anstalt gGmbH Bochum, Dept Haematol Oncol & Palliat Care, Bochum, Germany

[10] Univ Hosp Essen, Dept Haematol, Essen, Germany

[11] Bruderkrankenhaus St Josef, Hematol & Oncol, Paderborn, Germany

[12] Klinikum Ernst von Bergmann, Potsdam, Germany

[13] CCRC, Dusseldorf, Germany

[14] Univ Hosp Salzburg, Salzburg, Austria

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2018年 / 18卷

关键词：

Indolent lymphoma; non-hodgkin-lymphoma; Bendamustine; Rituximab maintenance;

D O I：

10.1016/j.clml.2018.06.072

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

FR-S26-NHL

引用

页码：S101 / S103

页数：3

共 49 条

[31] Rituximab Maintenance Compared With Observation After Brief First-Line R-FND Chemoimmunotherapy With Rituximab Consolidation in Patients Age Older Than 60 Years With Advanced Follicular Lymphoma: A Phase III Randomized Study by the Fondazione Italiana Linfomi
Vitolo, Umberto
Ladetto, Marco
Boccomini, Carola
Baldini, Luca
De Angelis, Federico
Tucci, Alessandra
Botto, Barbara
Chiappella, Annalisa
Chiarenza, Annalisa
Pinto, Antonello
De Renzo, Amalia
Zaja, Francesco
Castellino, Claudia
Bari, Alessia
De Celis, Isabel Alvarez
Evangelista, Andrea
Parvis, Guido
Gamba, Enrica
Lobetti-Bodoni, Chiara
Ciccone, Giovannino
Rossi, Giuseppe
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (27) : 3351 - +
[32] Front-line brief chemo-immunotherapy rituximab (R)-FND plus rituximab consolidation ± rituximab maintenance in elderly patients with untreated advanced stage follicular lymphoma (FL):: First interim analysis of a prospective randomized study (ML17638)
Vitolo, Umberto
Ladetto, Marco
Gamba, Enrica
Baldini, Luca
Ceccarelli, Manuela
Chiappella, Annalisa
De Renzo, Amalia
Di Raimondo, Francesco
Gallamini, Andrea
Guarini, Attilio
Mantoan, Barbara
Martelli, Maurizio
Alvarez, Isabel
Orsucci, Lorella
Parvis, Guido
Petrini, Mario
Pinto, Antonello
Pogliani, Enrico Maria
Pozzi, Samantha
Pulsoni, Alessandro
Rigacci, Luigi
Tucci, Alessandra
Zaja, Francesco
Gallo, Eugenio
BLOOD, 2007, 110 (11) : 384A - 384A
[33] MAGNIFY: A randomized, phase 3b trial in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) investigating lenalidomide plus rituximab (R2) induction followed by maintenance R2 followed by lenalidomide versus R2 induction followed by rituximab (R) maintenance.
Andorsky, David Jacob
Franson, Paula J.
Mouro, Jorge L.
Li, Jiahui
Foon, Kenneth A.
Sharman, Jeff Porter
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[34] First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4
Walewski, Jan
Paszkiewicz-Kozik, Ewa
Michalski, Wojciech
Rymkiewicz, Grzegorz
Szpila, Tomasz
Butrym, Aleksandra
Giza, Agnieszka
Zaucha, Jan M.
Kalinka-Warzocha, Ewa
Wieczorkiewicz, Agata
Zimowska-Curylo, Dagmara
Knopinska-Posluszny, Wanda
Tyczynska, Agata
Romejko-Jarosinska, Joanna
Dabrowska-Iwanicka, Anna
Gruszecka, Beata
Jamrozek-Jedlinska, Maria
Borawska, Anna
Holda, Waldemar
Porowska, Agnieszka
Romanowicz, Agnieszka
Hellmann, Andrzej
Stella-Holowiecka, Beata
Deptala, Andrzej
Jurczak, Wojciech
BRITISH JOURNAL OF HAEMATOLOGY, 2020, 188 (06) : 898 - 906
[35] Phase IIIb randomized study of lenalidomide plus rituximab (R2) followed by maintenance in relapsed/refractory NHL: Analysis of patients with double-refractory or early relapsed follicular lymphoma (FL).
Andorsky, David Jacob
Yacoub, Abdulraheem
Melear, Jason M.
Coleman, Morton
Kolibaba, Kathryn S.
Brooks, Heather Dawn
Bitran, Jacob D.
Fanning, Suzanne R.
Lansigan, Frederick
Ricker, Justin L.
Foon, Kenneth A.
Liu, Dongfang
Llorente, Mary
Li, Jiahui
Sharman, Jeff Porter
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[36] Bendamustine Plus Rituximab Is Superior in Respect of Progression Free Survival and CR Rate When Compared to CHOP Plus Rituximab as First-Line Treatment of Patients with Advanced Follicular, Indolent, and Mantle Cell Lymphomas: Final Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany)
Rummel, Mathias J.
Niederle, Norbert
Maschmeyer, Georg
Banat, Andre
von Gruenhagen, Ulrich
Losem, Christoph
Heil, Gerhard
Welslau, Manfred
Balser, Christina
Kaiser, Ulrich
Ballo, Harald
Weidmann, Eckhart
Duerk, Heinz A.
Kofahl-Krause, Dorothea
Roller, Fritz
Barth, Juergen
Hoelzer, Dieter
Hinke, Axel
Brugger, Wolfram
BLOOD, 2009, 114 (22) : 168 - 169
[37] Primary Results from Phase 3, Double-Blind, Placebo-Controlled SHINE Trial: Ibrutinib (Ibr) in Combination with Bendamustine-Rituximab (BR) and R-Maintenance as First-Line Treatment (1L) in Elderly Patients with Mantle Cell Lymphoma (MCL)
Dreyling, M.
Jurczak, W.
Jerkeman, M.
Trotman, J.
Zinzani, P. L.
Belada, D.
Boccomini, C.
Flinn, I. W.
Giri, P.
Goy, A.
Hamlin, P. A.
Hermine, O.
Hernandez-Rivas, J. -A
Hong, X.
Kim, S. J.
Lewis, D.
Mishima, Y.
Oezcan, M.
Perini, G. F.
Pocock, C.
Song, Y.
Spurgeon, S. E.
Storring, J. M.
Walewski, J.
Zhu, J.
Qin, R.
Henninger, T.
Deshpande, S.
Howes, A.
Le, Gouill S.
Wang, M. L.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 149 - 150
[38] First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study
Flinn, Ian W.
van der Jagt, Richard
Kahl, Brad
Wood, Peter
Hawkins, Tim
MacDonald, David
Simpson, David
Kolibaba, Kathryn
Issa, Samar
Chang, Julie
Trotman, Judith
Hallman, Doreen
Chen, Ling
Burke, John M.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (12) : 984 - +
[39] First-line rituximab (R) high-dose therapy (R-HDT) versus R-CHOP14 for young adults with diffuse large B-cell lymphoma: Preliminary results of the GOELAMS 075 prospective multicenter randomized trial
Le Gouill, S.
Milpied, N. J.
Lamy, T.
Delwail, V.
Gressin, R.
Guyotat, D.
Damaj, G. L.
Foussard, C.
Cartron, G.
Maisonneuve, H.
Deconinck, E.
Dreyfus, F.
Gyan, E.
Sutton, L.
Morineau, N.
Alexis, M.
Perry, F.
Sauvezie, M.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[40] Primary results from the double-blind, placebo-controlled, phase III SHINE study of ibrutinib in combination with bendamustine-rituximab (BR) and R maintenance as a first-line treatment for older patients with mantle cell lymphoma (MCL).
Wang, Michael
Jurczak, Wojciech
Jerkeman, Mats
Trotman, Judith
Zinzani, Pier Luigi
Walewski, Jan Andrzej
Zhu, Jun
Spurgeon, Stephen
Goy, Andre
Hamlin, Paul A.
Belada, David
Ozcan, Muhit
Storring, John
Lewis, David John
Rivas, Jose Angel Hernandez
Henninger, Todd
Deshpande, Sanjay
Qin, Rui
Le Gouill, Steven
Dreyling, Martin H.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)

← 1 2 3 4 5 →